Ivan Hyep, Chief Monetary Officer of Bicara Therapeutics Inc. (), offered 9,200 shares of the corporate’s widespread inventory on Might 21, 2026, for a complete worth of $187,883. The shares have been offered at a weighted common worth of $20.4221 per share, with particular person transaction costs starting from $20.25 to $20.61.
This sale was executed pursuant to a pre-arranged Rule 10b5-1 buying and selling plan, which was adopted on February 13, 2025. The timing comes as BCAX shares commerce at $21.98, up 137% over the previous yr, in response to InvestingPro knowledge. An InvestingPro tip highlights the inventory’s “excessive return during the last yr,” although the platform’s Honest Worth evaluation suggests the shares could also be overvalued at present ranges.
Instantly previous to the sale, Mr. Hyep acquired the identical 9,200 shares of widespread inventory on Might 21, 2026, by the train of inventory choices. These shares have been acquired at a worth of $3.7898 per share, totaling $34,866. This selection train was additionally a part of the Rule 10b5-1 buying and selling plan.
The underlying choices for these shares vest in sixteen equal quarterly installments following August 8, 2023, topic to Mr. Hyep’s continued service. The choices have an expiration date of August 8, 2033.
Following these transactions, Mr. Hyep immediately holds 145,355 shares of Bicara Therapeutics widespread inventory. He additionally retains 70,584 inventory choices.
In different current information, Bicara Therapeutics Inc. reported its first-quarter 2026 monetary outcomes, which fell in need of analyst expectations. The corporate introduced an earnings per share of -$0.93, lacking forecasts and leading to a pre-market inventory decline. Regardless of this, Bicara emphasised its sturdy money place and continued progress in medical trials, notably for its lead product, FICERA. Moreover, Bicara offered prolonged follow-up knowledge from a Part 1/1b research on the 2026 American Society of Scientific Oncology Annual Assembly, exhibiting a 31% three-year survival price for sufferers on a particular dose of ficerafusp alfa mixed with pembrolizumab.
Analyst corporations have reacted to those developments with assorted outlooks. Residents reiterated a Market Outperform score and a $31.00 worth goal, citing ongoing trial progress. In the meantime, Stifel lowered its worth goal from $48 to $46 however maintained a Purchase score, anticipating additional knowledge from upcoming shows. These current developments present buyers with perception into Bicara’s ongoing medical efforts and monetary efficiency.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
